Delfi Liquid Biopsy Shows Promise for Reducing Lung Cancer Deaths

News provided by

Aug 20, 2021, 08:02 ET

BALTIMORE and PALO ALTO, Calif., Aug. 20, 2021 /PRNewswire/ -- A novel machine learning based blood testing technology that could help to increase detection of early-stage lung cancer demonstrated promising results in a study published in Nature Communications¹. Delfi Diagnostics Inc.'s lung cancer screening technology, which uses advanced machine learning algorithms to analyze genome-wide cell-free DNA fragmentation profiles, was able to detect approximately 90% of cancer cases in a group of nearly 800 individuals who underwent lung cancer screening with a low-dose CT (LDCT) scan.

Lung cancer is the leading cause of cancer deaths, with the vast majority of lung cancers detected at late stages when prognosis is poor. LDCT scans have proven to be effective in lowering overall mortality among those at high risk for developing the disease, by detecting cancer early. Recently, the USPSTF expanded its existing lung screening guidance to include high risk individuals 50 years old and over, increasing the recommended population to 15 million U.S. adults.

Despite this guidance, fewer than 6% of those individuals receive the recommended screening. Researchers estimate that hundreds of thousands of deaths could be prevented world-wide through improved screening and early detection.

"These results suggest that the Delfi lung cancer screening technology could help reduce lung cancer deaths by offering a convenient, high-performing test to people who are USPSTF eligible," said Delfi CMO Peter B. Bach, MD. "We have already begun enrollment of a 1,700-patient, prospective, case-control study (DELFI-L101) to generate the clinical evidence that would underpin a commercial lung screening test."

The Nature Communications study evaluated 365 individuals participating in a seven-year Danish study called LUCAS, with the majority of participants at high-risk for lung cancer and with smoking-related symptoms such as cough or difficulty breathing. The results were validated in a separate study of 431 individuals with and without cancer with similar test performance.

When the Delfi technology was used as a pre-screen to determine if an LDCT should be performed, the combined approach led to detection of 90% of lung cancers, including 80% of stage I cancers, and reduced the number of LDCT induced unnecessary procedures by 50%.

"Because blood tests are so much easier to administer than LDCT, we believe a high-performing, cost effective assay could greatly increase the number of lung cancers that are detected early, when it can make a difference in care and eliminate a great deal of false positives compared to the current standard of care," said Nic Dracopoli, Delfi's Chief Scientific Officer and author on the publication. "The test is particularly well suited to lung cancer screening because we've shown it can detect both SCLC and NSCLC without inadvertently detecting other lung diseases such as COPD."

Delfi is developing a new class of liquid biopsy for early detection based on altered genome-wide fragmentation profiles, also known as "fragmentomes," a result of disordered packaging of DNA in cancer cells. Delfi is developing a highly sensitive and specific assay intended for wide and cost-effective distribution and adoption by applying an advanced machine learning algorithm to the circulating DNA fragment patterns that can be assessed via low-cost sequencing. To learn more, visit www.DelfiDiagnostics.com